

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM357880

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
RESUBMIT DOCUMENT ID:	900339480

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Willington Trust, National Association		09/16/2013	CORPORATION:

RECEIVING PARTY DATA

Name:	Drugtech Corporation
Doing Business As:	Lumara Health IP Ltd
Street Address:	16640 Chesterfield Grove Road
Internal Address:	Suite 200
City:	Chesterfield
State/Country:	MISSOURI
Postal Code:	63005
Entity Type:	CORPORATION: DELAWARE

PROPERTY NUMBERS Total: 41

Property Type	Number	Word Mark
Registration Number:	2517899	CALCIPURE
Registration Number:	1156939	CHROMAGEN
Registration Number:	3395236	CHRONOMETRIC SYSTEM
Registration Number:	3184560	CLINDESSE
Registration Number:	2948258	CONTINUUM OF CARE
Registration Number:	3111521	ENCORA
Registration Number:	3688522	EVAMIST
Registration Number:	3550530	EVAMIST
Registration Number:	1997221	FLAVORTECH
Registration Number:	1912198	GUAIFENEX
Registration Number:	2457708	GYNAZOLE 1
Registration Number:	2031080	HISTA-VENT
Registration Number:	1932221	HISTINEX
Registration Number:	4317346	KV PHARMACEUTICAL
Registration Number:	1293848	METER RELEASE
Registration Number:	1939204	MICRO RELEASE

TRADEMARK

Property Type	Number	Word Mark
Registration Number:	2031082	NATALCARE
Registration Number:	0804556	NIFEREX
Registration Number:	3291637	NIFEREX GOLD
Registration Number:	2441392	NUTRINATE
Registration Number:	2940425	OMEGANATE
Registration Number:	2719613	PRE CARE CONCEIVE
Registration Number:	1365182	PRECARE
Registration Number:	3320970	PRECARE PREMIER
Registration Number:	2582817	PRIMACARE
Registration Number:	3643470	PRIMACARE ADVANTAGE
Registration Number:	3414475	PRIMACARE ONE
Registration Number:	3406639	REPLIVA
Registration Number:	3389789	REPLIVA 21/7
Registration Number:	1192702	SITE RELEASE
Registration Number:	2742749	STRONGSTART
Registration Number:	4254188	THER-RX
Registration Number:	2948813	THE THER-RX CONTINUUM OF WOMEN'S CARE
Serial Number:	77558671	KV
Serial Number:	77558677	KV PHARMACEUTICAL
Serial Number:	77519812	EVAMIST
Serial Number:	77558690	KV
Serial Number:	77558695	KV PHARMACEUTICAL
Serial Number:	77558703	KV PHARMACEUTICAL
Serial Number:	77466451	LIQUETTE
Serial Number:	77885809	PREMESISRX

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: PeterHart@goodwinprocter.com

Correspondent Name: Goodwin Procter LLP c/o Peter Hart

Address Line 1: The New York Times Building

Address Line 2: 620 Eighth Avenue

Address Line 4: New York, NEW YORK 10018

NAME OF SUBMITTER: Peter Hart

SIGNATURE: /Peter Hart/

DATE SIGNED: 10/08/2015

Total Attachments: 10

source=25. WTC Trademark Release#page1.tif
source=25. WTC Trademark Release#page2.tif
source=25. WTC Trademark Release#page3.tif
source=25. WTC Trademark Release#page4.tif
source=25. WTC Trademark Release#page5.tif
source=24. WTC Patent Release#page1.tif
source=24. WTC Patent Release#page2.tif
source=24. WTC Patent Release#page3.tif
source=24. WTC Patent Release#page4.tif
source=24. WTC Patent Release#page5.tif

**RELEASE OF SECURITY INTEREST IN
TRADEMARKS**

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS (the "Release"), is granted and conveyed as of this 16 day of September, 2013, by Wilmington Trust, National Association (successor by merger to Wilmington Trust FSB), as collateral agent (the "Agent"), in favor of DrugTech Corporation, a Delaware corporation (the "Obligor").

WITNESSETH:

WHEREAS, pursuant to that certain Pledge and Security Agreement, dated as of March 17, 2011, by and among the parties and the other grantors party thereto (the "Security Agreement"), the Obligor granted to the Agent security interests in certain collateral, including the Trademark Collateral (as hereinafter defined);

WHEREAS, in connection with the Security Agreement, the Obligor executed that certain Trademark Security Agreement, dated as of March 17, 2011 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Trademark Security Agreement"), under which the Obligor mortgaged, pledged and granted to the Agent a lien on, and security interest in and to, all of Obligor's right, title and interest in, to and under the Trademark Collateral (together with the security interests granted pursuant to the Security Agreement, the "Security Interests"), for recording with the United States Patent and Trademark Office and any other appropriate governmental authorities;

WHEREAS, the Trademark Security Agreement was recorded in the United States Patent and Trademark Office on March 18, 2011 at Reel 4501/Frame 0167;

WHEREAS, pursuant to that certain Order Confirming Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and its Affiliated Debtors (the "Order"), entered in the United States Bankruptcy Court, Southern District of New York on August 29, 2013 in connection with the Sixth Amended Joint Chapter 11 Plan of Reorganization of K-V Discovery Solutions and its Affiliated Debtors, dated July 17, 2013 (the "Plan"), the Obligor and Agent are authorized, upon the Effective Date (as defined in the Plan), to: (a) terminate and release all liens and interests of the Agent in the Trademark Collateral and (b) execute and deliver evidence of such termination and release for filing in the United States Patent and Trademark Office;

WHEREAS, all conditions to the occurrence of the Effective Date (as defined in the Plan) have occurred and the Effective Date (as defined in the Plan) is the same as the date of this Release; and

WHEREAS, all conditions to the release of the Agent's Security Interests in the Trademark Collateral have been satisfied, and the parties seek to make record of the Agent's release to the Obligor of any and all of its Security Interests in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Definitions. All capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Security Agreement. The term “Trademark Collateral,” as used herein, shall mean (a) all of the Obligor’s right, title and interest in and to the trademarks, trademark registrations, and trademark applications listed on Schedule A hereto, and all of the goodwill of the business connected with the use of, and symbolized by, each such trademark, trademark registration and trademark application; (b) all renewals of the foregoing; and (c) all proceeds of the foregoing, including without limitation any claim against third parties for damages by reason of past, present or future infringement or dilution of any trademark, trademark registration, or trademark application listed on Schedule A hereto or by reason of injury to the goodwill associated with any such trademark, trademark registration, or trademark application, in each case together with the right to sue for and collect said damages.

2. Release of Security Interests. The Agent hereby terminates, discharges and releases to the Obligor the Security Interests in the Trademark Collateral, and any right, title or interest of the Agent in such Trademark Collateral shall hereby cease and become void.


3. Further Assurances. The Agent hereby agrees to duly execute, acknowledge, procure and deliver, at the sole expense of the Obligor or its successors and assigns, any further documents and to do such other acts as may be reasonably necessary to effect the termination, release, discharge or reassignment to the Obligor of the Security Interests contemplated hereby.

4. Governing Law. This Release shall be governed by, and construed in accordance with, the laws of the State of New York.

[signature page follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

WILMINGTON TRUST, NATIONAL
ASSOCIATION (successor by merger to
Wilmington Trust FSB), as Agent

By: 
Name: Peter Pinkert
Title: V.P.

[Signature Page to Release of Security Interest in Trademarks]

SCHEDULE A**TRADEMARKS**

Trademark	Registration No.	Registration Date	Owner
CALCIPURE	2,517,899	12/11/2001	Drugtech Corporation
CHROMAGEN	1,156,939	6/9/1981	
CHRONOMETRIC SYSTEM	3,395,236	3/11/2008	Drugtech Corporation
CLINDESSE	3,184,560	12/12/2006	Drugtech Corporation
CONTINUUM OF CARE	2,948,258	5/10/2005	Drugtech Corporation
ENCORA	3,111,521	7/4/2006	Drugtech Corporation
EVAMIST and Design	3,688,522	9/29/2009	Drugtech Corporation
EVAMIST	3,550,530	12/23/2008	Drugtech Corporation
FLAVORTECH (Stylized)	1,997,221	8/27/1996	Drugtech Corporation
GUAIFENEX	1,912,198	8/15/1995	Drugtech Corporation
GYNAZOLE 1	2,457,708	6/5/2001	Drugtech Corporation
HISTA-VENT	2,031,080	1/14/1997	Drugtech Corporation
HISTINEX	1,932,221	10/31/1995	Drugtech Corporation
KV PHARMACEUTICAL and Design	4,317,346	4/9/2013	Drugtech Corporation
METER RELEASE	1,293,848	9/11/1984	Drugtech Corporation
MICRO RELEASE	1,939,204	12/5/1995	Drugtech Corporation
NATALCARE	2,031,082	1/14/1997	Drugtech Corporation
NIFEREX (Stylized)	804,556	3/1/1966	Drugtech Corporation
NIFEREX GOLD	3,291,637	9/11/2007	Drugtech Corporation
NUTRINATE	2,441,392	4/3/2001	Drugtech Corporation

OMEGANATE	2,940,425	4/12/2005	Drugtech Corporation
PRE CARE CONCEIVE	2,719,613	5/27/2003	Drugtech Corporation
PRECARE	1,365,182	10/15/1985	Drugtech Corporation
PRECARE PREMIER	3,320,970	10/23/2007	Drugtech Corporation
PRIMACARE	2,582,817	6/18/2002	Drugtech Corporation
PRIMACARE ADVANTAGE	3,643,470	6/23/2009	Drugtech Corporation
PRIMACARE ONE	3,414,475	4/22/2008	Drugtech Corporation
REPLIVA	3,406,639	4/1/2008	Drugtech Corporation
REPLIVA 21/7	3,389,789	2/26/2008	Drugtech Corporation
SITE RELEASE	1,192,702	3/30/1982	Drugtech Corporation
STRONGSTART	2,742,749	7/29/2003	Drugtech Corporation
THER-RX	4,254,188	12/4/2012	Drugtech Corporation
THE THE-RX CONTINUUM OF WOMEN'S CARE and Design	2,948,813	5/10/2005	Drugtech Corporation

U.S. Trademark Applications

Trademark	Application No.	Application Date	Owner
KV	77/558,671	8/29/2008	Drugtech Corporation
KV PHARMACEUTICAL	77/558,677	8/29/2008	Drugtech Corporation
EVAMIST	77/519,812	7/10/2008	Drugtech Corporation
KV	77/558,690	8/29/2008	Drugtech Corporation
KV PHARMACEUTICAL	77/558,695	8/29/2008	Drugtech Corporation
KV PHARMACEUTICAL	77/558,703	8/29/2008	Drugtech Corporation
LIQUETTE	77/466,451	5/6/2008	Drugtech Corporation
PREMESISRX	77/885,809	12/3/2009	Drugtech Corporation

**RELEASE OF SECURITY INTEREST IN
PATENTS**

THIS RELEASE OF SECURITY INTEREST IN PATENTS (the "Release"), is granted and conveyed as of this 16 day of September, 2013, by Wilmington Trust, National Association (successor by merger to Wilmington Trust FSB), as collateral agent (the "Agent"), in favor of DrugTech Corporation, a Delaware corporation (the "Obligor").

WITNESSETH:

WHEREAS, pursuant to that certain Pledge and Security Agreement, dated as of March 17, 2011, by and among the parties and the other grantors party thereto (the "Security Agreement"), the Obligor granted to the Agent security interests in certain collateral, including the Patent Collateral (as hereinafter defined);

WHEREAS, in connection with the Security Agreement, the Obligor executed that certain Patent Security Agreement, dated as of March 17, 2011 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Patent Security Agreement"), under which the Obligor mortgaged, pledged and granted to the Agent a lien on, and security interest in and to, all of Obligor's right, title and interest in, to and under the Patent Collateral (together with the security interests granted pursuant to the Security Agreement, the "Security Interests"), for recording with the United States Patent and Trademark Office and any other appropriate governmental authorities;

WHEREAS, the Patent Security Agreement was recorded in the United States Patent and Trademark Office on March 18, 2011 at Reel 025981/Frame 0068;

WHEREAS, pursuant to that certain Order Confirming Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and its Affiliated Debtors (the "Order"), entered in the United States Bankruptcy Court, Southern District of New York on August 29, 2013 in connection with the Sixth Amended Joint Chapter 11 Plan of Reorganization of K-V Discovery Solutions and its Affiliated Debtors, dated July 17, 2013 (the "Plan"), the Obligor and Agent are authorized, upon the Effective Date (as defined in the Plan), to: (a) terminate and release all liens and interests of the Agent in the Patent Collateral and (b) execute and deliver evidence of such termination and release for filing in the United States Patent and Trademark Office;

WHEREAS, all conditions to the occurrence of the Effective Date (as defined in the Plan) have occurred and the Effective Date (as defined in the Plan) is the same as the date of this Release; and

WHEREAS, all conditions to the release of the Agent's Security Interests in the Patent Collateral have been satisfied, and the parties seek to make record of the Agent's release to the Obligor of any and all of its Security Interests in the Patent Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Definitions. All capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Security Agreement. The term “Patent Collateral,” as used herein, shall mean (a) all of the Obligor’s right, title and interest in and to the patents and patent applications listed on Schedule A hereto, including any divisionals, continuations, continuations-in-part, reissues, reexaminations or corresponding foreign patents and patent applications; (b) all renewals thereof; and (c) all proceeds of the foregoing, including without limitation any claim against third parties for damages by reason of past, present or future infringement of any patent or patent application listed on Schedule A hereto, together with the right to sue for and collect said damages.

2. Release of Security Interests. The Agent hereby terminates, discharges and releases to the Obligor the Security Interests in the Patent Collateral, and any right, title or interest of the Agent in such Patent Collateral shall hereby cease and become void.


3. Further Assurances. The Agent hereby agrees to duly execute, acknowledge, procure and deliver, at the sole expense of the Obligor or its successors and assigns, any further documents and to do such other acts as may be reasonably necessary to effect the termination, release, discharge or reassignment to the Obligor of the Security Interests contemplated hereby.

4. Governing Law. This Release shall be governed by, and construed in accordance with, the laws of the State of New York.

[signature page follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

WILMINGTON TRUST, NATIONAL
ASSOCIATION (successor by merger to
Wilmington Trust FSB), as Agent

By: 
Name: Robert F. Tucker
Title: V.P.

[Signature Page to Release of Security Interest in Patents]

SCHEDULE A**PATENTS****Patents**

Title	Patent No.	Issue Date	Owner
Long Acting GI and Esophageal Protectant	5,554,379	9/10/1996	Drugtech Corporation
Multi-Vitamin and Mineral Supplement for Pregnant Women	5,494,678	2/27/1996	Drugtech Corporation
Long Acting GI and Esophageal Protectant	5,670,163	9/23/1997	Drugtech Corporation
Bioadhesive Pharmaceutical Delivery System	5,554,380	9/10/1996	Drugtech Corporation
Multi-Vitamin and Mineral Supplements for Women	5,869,084	2/9/1999	Drugtech Corporation
Long Acting GI and Esophageal Protectant	5,858,391	1/12/1999	Drugtech Corporation
Vitamin/Nutrient Dosage Regimentation	6,696,083	2/24/2004	Drugtech Corporation
Maximizing Effectiveness of Substances Used to Improve Health and Well Being	5,945,123	8/31/1999	Drugtech Corporation
Folic Acid Supplement	6,261,600	7/17/2001	Drugtech Corporation
Dietary Supplement	6,569,857	5/27/2003	Drugtech Corporation
Anti-Nausea Compositions and Methods	6,197,329	3/6/2001	Drugtech Corporation
Maximizing Effectiveness of Substances Used to Improve Health and Well Being	6,214,379	4/10/2001	Drugtech Corporation
Nutritional Supplements	6,258,846	7/10/2001	Drugtech Corporation

Strip Pack	6,375,956	4/23/2002	Drugtech Corporation
Formulation for Menopausal Women	6,479,545	11/12/2002	Drugtech Corporation
Multi-Vitamin and Mineral Supplements for Women	6,488,956	12/3/2002	Drugtech Corporation
Nutritional Composition	6,352,713	3/5/2002	Drugtech Corporation
Composition with Sustained Release of Levodopa and Carbidopa	6,531,153	3/11/2003	Drugtech Corporation
Nutritional Supplements	6,576,666	6/10/2003	Drugtech Corporation
Mineral Supplement	6,793,935	9/21/2004	Drugtech Corporation
Bioadhesive Drug Delivery System	6,899,890	5/31/2005	Drugtech Corporation
Formulation for Menopausal Women	7,687,485	3/30/2010	Drugtech Corporation
Nutritional Supplements	7,112,609	9/26/2006	Drugtech Corporation
Rapidly Disintegrable Tablets	7,282,217	10/16/2007	Drugtech Corporation
Delivery System	8,057,433	11/15/2011	Drugtech Corporation
Methods for Determining Absorption of Cobalamin or Analogues Thereof	7,727,972	6/1/2010	Drugtech Corporation
Rapidly Disintegrable Tablets	7,425,341	9/16/2008	Drugtech Corporation

Patent Applications

Title	Application No.	Application Date	Owner
Methods for Administering Compositions Including Iron	12-891376	9/27/2010	Drugtech Corporation
Transdermal, Alcohol-Free, Pharmaceutical Compositions	12-209864	9/12/2008	Drugtech Corporation